EP Patent

EP3481397A1 — Deuterated venetoclax

Assigned to Concert Pharmaceuticals Inc · Expires 2019-05-15 · 7y expired

What this patent protects

This invention relates to deuterated forms of venetoclax, and pharmaceutically acceptable salts thereof. Certain aspects of this invention also provide pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier. Certain as…

USPTO Abstract

This invention relates to deuterated forms of venetoclax, and pharmaceutically acceptable salts thereof. Certain aspects of this invention also provide pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier. Certain aspects of the present invention also provide the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of the anti-apoptotic activity of the B-cell lymphoma 2 (Bcl-2) protein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3481397A1
Jurisdiction
EP
Classification
—
Expires
2019-05-15
Drug substance claim
No
Drug product claim
No
Assignee
Concert Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.